|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-3-8
|
|
pubmed:abstractText |
Secretory leukocyte protease inhibitor (SLPI) has been found to possess activity against the human immunodeficiency virus type 1 (HIV-1) in vitro at physiological concentrations. A study was undertaken to evaluate SLPI levels in human saliva and plasma among HIV-positive (HIV(+)) patients with various HIV-1 viral loads in comparison to uninfected controls. Whole blood in EDTA and unstimulated saliva samples were collected from 37 HIV(+) patients, of whom 20 had a history of intravenous drug abuse (IVDA). Control samples were collected from 20 appropriate age- and sex-matched HIV-1-negative individuals. SLPI was estimated from both saliva and serum samples by an enzyme-linked immunosorbent assay. HIV viral load was determined using a quantitative reverse transcription-PCR. SLPI levels were increased 16.7% in plasma and 10.3% in saliva among HIV(+) patients in comparison to uninfected controls. SLPI levels were increased 5.9% in saliva and 3.9% in plasma among HIV(+) patients with a high viral load (>10,000 copies/ml) as compared to patients with a low viral load (<400 copies/ml). Only 23% of patients with a high viral load used combination therapy with protease inhibitor drugs, whereas 92.9% of HIV(+) patients with a low viral load used protease inhibitors. SLPI levels did not differ significantly among the IVDA patients, patients with different viral loads, or patients using protease inhibitor drugs. There was a statistically significant increase in SLPI levels in saliva among HIV patients in comparison to non-HIV-infected controls. An increase in SLPI levels among HIV(+) patients may be a natural consequence of HIV pathogenesis and an important factor in preventing oral transmission of HIV, but this increase may not be evident during plasma viremia in patients with a high viral load.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-2078420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-2461824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-2738248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-3036953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-3164028,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-3422106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-3456076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-7615818,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-7887550,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8080437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8145793,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8373999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8396401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8397002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-8409011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-9201260,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10548568-9242546
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1071-412X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
808-11
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10548568-Adult,
pubmed-meshheading:10548568-Anti-HIV Agents,
pubmed-meshheading:10548568-Female,
pubmed-meshheading:10548568-HIV Infections,
pubmed-meshheading:10548568-HIV-1,
pubmed-meshheading:10548568-Humans,
pubmed-meshheading:10548568-Male,
pubmed-meshheading:10548568-Middle Aged,
pubmed-meshheading:10548568-Protease Inhibitors,
pubmed-meshheading:10548568-Proteinase Inhibitory Proteins, Secretory,
pubmed-meshheading:10548568-Proteins,
pubmed-meshheading:10548568-Saliva,
pubmed-meshheading:10548568-Secretory Leukocyte Peptidase Inhibitor,
pubmed-meshheading:10548568-Viral Load
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
|
|
pubmed:affiliation |
Department of Oral Medicine, Dental School, University of Maryland, Baltimore, Maryland 21201, USA. aab001@dental.umaryland.edu
|
|
pubmed:publicationType |
Journal Article
|
